Last reviewed · How we verify
Trilipix (CHOLINE FENOFIBRATE)
Trilipix (Choline Fenofibrate) is a peroxisome proliferator receptor alpha agonist, originally developed by Abbvie and currently owned by the same company. It targets the fatty acid-binding protein in the intestine to lower cholesterol and triglyceride levels in the blood. Trilipix is approved to treat various lipid disorders, including familial hypercholesterolemia, hypercholesterolemia, and hypertriglyceridemia. The drug is now off-patent, with multiple generic manufacturers available. Key safety considerations include monitoring liver function and potential interactions with other medications.
At a glance
| Generic name | CHOLINE FENOFIBRATE |
|---|---|
| Sponsor | AbbVie |
| Drug class | Peroxisome Proliferator Receptor alpha Agonist |
| Target | Fatty acid-binding protein, intestinal |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 2008 |
Approved indications
- Familial hypercholesterolemia - heterozygous
- Hypercholesterolemia
- Hyperlipidemia
- Hypertriglyceridemia
- Hypoalphalipoproteinemia
- Mixed hyperlipidemia
Common side effects
- Headache
- Nausea
- Diarrhea
- Dyspepsia
- Constipation
- Back pain
- Nasopharyngitis
- Myalgia
- Upper respiratory tract infection
- Bronchitis
- Influenza
- Urinary tract infection
Serious adverse events
- Rhabdomyolysis
- Pancreatitis
- Renal failure
- Acute renal failure
- Hepatitis
- Cirrhosis
- Increased creatine phosphokinase
- Increased alanine aminotransaminase
- Increased aspartate aminotransaminase
- Muscle spasms
Key clinical trials
- Choline Fenofibrate and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia (PHASE4)
- Cinical Trial to Explore the Efficacy of Statin/Choline Fenofibrate Combination Therapy vs Statin Monotherapy in Patients With Inadequately Controlled TG Despite Receiving Statin Monotherapy (PHASE4)
- Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood (PHASE3)
- A Clinical Trial to Assess the Effects of Food on the Bioavailability of CKD-337 (PHASE1)
- A Clinical Trial to Compare Safety and Pharmacokinetic Characteristics of CKD-337 (PHASE1)
- Efficacy Study of Diazoxide Choline to Treat Hypertriglyceridemia (PHASE2)
- Effect of Choline Fenofibrate (SLV348) on Macular Edema (PHASE2)
- Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |